Why is Beryl Drugs falling/rising?

As of 15-Jul, Beryl Drugs Ltd's stock price is currently at 21.22, showing no change (0.00%). The stock has underperformed its sector today by 1.25%, and while it is higher than the 20-day and 50-day moving averages, it is lower than the 5-day, 100-day, and 200-day moving averages. Over the past week, the stock has decreased by 5.86%, but it has seen a positive return of 5.62% over the past month. Despite a significant decline of 33.69% over the past year, the stock is trading at a discount compared to its peers' average historical valuations. However, the company's weak long-term fundamental strength, indicated by a low average Return on Capital Employed (ROCE) of 7.27% and a poor EBIT to Interest ratio of 0.82, raises concerns about its ability to service debt and sustain growth.
In the broader market context, the stock's recent performance contrasts sharply with the benchmark, as it has underperformed the market significantly over the last year, where the BSE500 has generated returns of 0.37%. The stock's liquidity appears adequate for trading, with a delivery volume increase of 7.23% against the 5-day average. However, the overall sentiment remains cautious due to the company's flat results and declining profits, which have fallen by 18% over the past year. This combination of factors contributes to the stock's current stagnation in price, reflecting investor concerns about its long-term viability amidst a challenging market environment.